Literature DB >> 7574931

Forty-year appraisal of gastrinoma. Back to the future.

E C Ellison1.   

Abstract

OBJECTIVE: The author analyzed potential survival determinants in gastrinoma to characterize a possible uniform staging system and to determine whether complete surgical resection improves expected survival. SUMMARY AND BACKGROUND DATA: Gastrinoma is an indolent yet malignant neuroendocrine tumor. The associated gastric acid hypersecretion can be controlled medically. Staging of gastrinoma is inconsistent and the role of surgical resection controversial.
METHODS: Seventy-four patients with gastrinoma with a minimum 5-year follow-up were assessed. Cox's proportional hazards regression model was used to examine the association of risk factors with survival.
RESULTS: The following factors had no effect on survival: age at diagnosis, sex, presence of lymph node metastases, associated multiple endocrine neoplasia, and method of ulcer treatment. The three unique determinants of survival were primary tumor size (relative risk, 1.534; p = 0.0005), liver metastases (relative risk, 2.947; p = 0.0209), and complete surgical resection (relative risk, 0.163; p = 0.0076). On the basis of these risk factors, a uniform staging system is proposed and predictive survival curves developed.
CONCLUSIONS: The primary determinants of survival in gastrinoma are the size of the primary tumor and liver metastases. Complete surgical resection reduces mortality, regardless of other factors.

Entities:  

Mesh:

Year:  1995        PMID: 7574931      PMCID: PMC1234884          DOI: 10.1097/00000658-199522240-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

Review 1.  Omeprazole.

Authors:  P N Maton
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

2.  Excisional therapy for ulcerogenic tumors of the duodenum: long-term results.

Authors:  H A Oberhelman
Journal:  Arch Surg       Date:  1972-04

3.  Extrapancreatic, extraintestinal gastrinoma: effective treatment by surgery.

Authors:  M M Wolfe; R W Alexander; J E McGuigan
Journal:  N Engl J Med       Date:  1982-06-24       Impact factor: 91.245

4.  Resection of gastrinoma in the Zollinger-Ellison syndrome.

Authors:  R F Barreras; E Mack; T Goodfriend; M Damm
Journal:  Gastroenterology       Date:  1982-05       Impact factor: 22.682

5.  Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course.

Authors:  D C Metz; M Kuchnio; D L Fraker; D J Venzon; G Jaffe; R T Jensen; M Stetler-Stevenson
Journal:  Gastroenterology       Date:  1993-09       Impact factor: 22.682

6.  Removal of mesenteric gastrinoma: a case report.

Authors:  M Miyata; K Nakao; T Sakamoto; T Tsumori; M Hamaji; S Himeno; Y Kawashima
Journal:  Surgery       Date:  1986-02       Impact factor: 3.982

7.  Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma.

Authors:  D L Fraker; J A Norton; H R Alexander; D J Venzon; R T Jensen
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

8.  Benign and malignant gastrinoma.

Authors:  B E Stabile; E Passaro
Journal:  Am J Surg       Date:  1985-01       Impact factor: 2.565

Review 9.  Role of pancreatoduodenectomy in the management of primary duodenal wall gastrinomas in patients with Zollinger-Ellison syndrome.

Authors:  R Delcore; S R Friesen
Journal:  Surgery       Date:  1992-12       Impact factor: 3.982

10.  Results of surgical management in 92 consecutive patients with Zollinger-Ellison syndrome.

Authors:  S Bonfils; J H Landor; M Mignon; P Hervoir
Journal:  Ann Surg       Date:  1981-12       Impact factor: 12.969

View more
  4 in total

1.  Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE).

Authors:  G Cadiot; G Bonnaud; R Lebtahi; L Sarda; P Ruszniewski; D Le Guludec; M Mignon
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 2.  Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.

Authors:  Robert T Jensen; Marc J Berna; David B Bingham; Jeffrey A Norton
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

3.  Zollinger-Ellison Syndrome.

Authors:  Patrick D. Hung; Mitchell L. Schubert; Anastasios A. Mihas
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

4.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.